Table I.
Summary of Covariates Evaluated in the Analysis
| Covariates | IgE–FEV1 model | IgE–FeNO model | ||
|---|---|---|---|---|
| N | Statistics | N | Statistics | |
| Age (years) | 722 | 46 (12–75) | 348 | 45 (12–75) |
| Body weight (kg) | 721 | 84.7 (40.5–150) | 348 | 86.3 (41.8–150) |
| Height (cm) | 722 | 164 (127–198) | 348 | 164 (140–198) |
| Sex | 722 | 348 | ||
| Male | 246 | 246 (34%) | 118 | 118 (34%) |
| Female | 476 | 476 (66%) | 230 | 230 (66%) |
| Race | 722 | 348 | ||
| White | 554 (77%) | 264 (75.9%) | ||
| Black | 138 (19%) | 66 (19.0%) | ||
| Asian or Pacific Islander | 16 (2.1%) | 11 (3.2%) | ||
| American Indian or Alaska native | 3 (0.4%) | 1 (0.3%) | ||
| Other | 11 (1.5%) | 6 (1.6%) | ||
| Baseline blood eosinophil count (109 cells/L) | 679 | 0.26 (0.03–2.96) | 324 | 0.26 (0.03–2.96) |
| Baseline FEF 25–75% (ml) | 720 | 1,570 (250–6,070) | 348 | 1,535 (270–5,680) |
| Baseline FVC (ml) | 722 | 2,770 (879–7,100) | 348 | 2,770 (1,020–6,640) |
| Predicted FEV1 (ml) | 722 | 3,012 (1,006–5,094) | 348 | 3,011 (1,563–4,933) |
| Baseline symptom score | 719 | 3.80 (1.0–6.7) | 348 | 3.83 (1.0–6.6) |
| Current smoking status | 722 | 348 | ||
| Smoking | 12 (1.7%) | 8 (2.3%) | ||
| Nonsmoking | 710 (98.3%) | 340 (97.7%) | ||
| Number of exacerbation requiring treatment (past year) | 722 | 348 | ||
| 0 | 16 (2.2%) | 6 (1.7%) | ||
| 1 | 384 (53.2%) | 188 (54.0%) | ||
| 2 | 152 (21.1%) | 74 (21.3%) | ||
| 3 | 94 (13.0%) | 46 (13.2%) | ||
| ≥4 | 76 (10.5%) | 34 (9.8%) | ||
| Asthma reversibility (% improvement from baseline after bronchodilator) | 702 | 7.5 (−48.1–112) | 342 | 7.4 (−17.2–89.0) |
| Duration of asthma (years) | 722 | 21 (0–71) | 348 | 22 (0–71) |
Data are presented as median (ranges) or n (percent)
N number of subjects having the covariate, FEF 25–75% forced expiratory flow during the middle half of the forced vital capacity, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s